Cargando…

Milder symptoms and shorter course in patients with re-positive COVID-19: A cohort of 180 patients from Northeast China

China experienced another widespread Coronavirus disease 2019 (COVID-19) outbreak recently caused by the Omicron variant, which is less severe but far more contagious than the other COVID-19 variants, leading local governments to focus efforts on eliminating the spread of the disease. Previous studi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hongyan, Zhu, Mingqin, Zhang, Peng, Yan, Xingjian, Niu, Junqi, Wang, Zhenyu, Cao, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593080/
https://www.ncbi.nlm.nih.gov/pubmed/36304945
http://dx.doi.org/10.3389/fmicb.2022.989879
_version_ 1784815078162300928
author Li, Hongyan
Zhu, Mingqin
Zhang, Peng
Yan, Xingjian
Niu, Junqi
Wang, Zhenyu
Cao, Jie
author_facet Li, Hongyan
Zhu, Mingqin
Zhang, Peng
Yan, Xingjian
Niu, Junqi
Wang, Zhenyu
Cao, Jie
author_sort Li, Hongyan
collection PubMed
description China experienced another widespread Coronavirus disease 2019 (COVID-19) outbreak recently caused by the Omicron variant, which is less severe but far more contagious than the other COVID-19 variants, leading local governments to focus efforts on eliminating the spread of the disease. Previous studies showed that after “recovering” from the virus, some patients could re-test positive for COVID-19 with nucleic acid tests, challenging the control of disease spread. In this study, we aimed to analyze the clinical and laboratory characteristics of re-positive COVID-19 patients in Northeast China. We retrospectively analyzed data from confirmed reverse transcription polymerase chain reaction (RT-PCR) re-positive COVID-19 patients who were admitted to the First Hospital of Jilin University, Jilin Province, China, from March to June 2022. Detailed clinical symptoms, medical history, anti-Corona Virus (CoV) IgG and IgM levels, and CoV nucleic acid cycle threshold (Ct) values during the re-positive period were collected and analyzed. A total of 180 patients were included in this study, including 62 asymptomatic cases and 118 mild cases. The cohort included 113 men and 67 women, with an average age of 45.73 years. The median time between recovery from the virus and re-positivity was 13 days. Our results showed that the proportion of re-positive patients with symptoms was lower, and the nucleic acid test-positive duration was shorter during the re-positive period. Furthermore, in patients with underlying disease, the proportion of patients with symptoms was higher, anti-CoV IgG levels were lower, and the total disease duration was longer. In conclusion, during the re-positive period, the symptoms were milder, and the CoV nucleic acid test-positive course was shorter. The concomitant underlying disease is an important factor associated with clinical symptoms, and the overall course of COVID-19 re-positive patients may be associated with lower anti-CoV IgG levels. Large-scale and multicenter studies are recommended to better understand the pathophysiology of recurrence in patients with COVID-19.
format Online
Article
Text
id pubmed-9593080
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95930802022-10-26 Milder symptoms and shorter course in patients with re-positive COVID-19: A cohort of 180 patients from Northeast China Li, Hongyan Zhu, Mingqin Zhang, Peng Yan, Xingjian Niu, Junqi Wang, Zhenyu Cao, Jie Front Microbiol Microbiology China experienced another widespread Coronavirus disease 2019 (COVID-19) outbreak recently caused by the Omicron variant, which is less severe but far more contagious than the other COVID-19 variants, leading local governments to focus efforts on eliminating the spread of the disease. Previous studies showed that after “recovering” from the virus, some patients could re-test positive for COVID-19 with nucleic acid tests, challenging the control of disease spread. In this study, we aimed to analyze the clinical and laboratory characteristics of re-positive COVID-19 patients in Northeast China. We retrospectively analyzed data from confirmed reverse transcription polymerase chain reaction (RT-PCR) re-positive COVID-19 patients who were admitted to the First Hospital of Jilin University, Jilin Province, China, from March to June 2022. Detailed clinical symptoms, medical history, anti-Corona Virus (CoV) IgG and IgM levels, and CoV nucleic acid cycle threshold (Ct) values during the re-positive period were collected and analyzed. A total of 180 patients were included in this study, including 62 asymptomatic cases and 118 mild cases. The cohort included 113 men and 67 women, with an average age of 45.73 years. The median time between recovery from the virus and re-positivity was 13 days. Our results showed that the proportion of re-positive patients with symptoms was lower, and the nucleic acid test-positive duration was shorter during the re-positive period. Furthermore, in patients with underlying disease, the proportion of patients with symptoms was higher, anti-CoV IgG levels were lower, and the total disease duration was longer. In conclusion, during the re-positive period, the symptoms were milder, and the CoV nucleic acid test-positive course was shorter. The concomitant underlying disease is an important factor associated with clinical symptoms, and the overall course of COVID-19 re-positive patients may be associated with lower anti-CoV IgG levels. Large-scale and multicenter studies are recommended to better understand the pathophysiology of recurrence in patients with COVID-19. Frontiers Media S.A. 2022-10-11 /pmc/articles/PMC9593080/ /pubmed/36304945 http://dx.doi.org/10.3389/fmicb.2022.989879 Text en Copyright © 2022 Li, Zhu, Zhang, Yan, Niu, Wang and Cao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Li, Hongyan
Zhu, Mingqin
Zhang, Peng
Yan, Xingjian
Niu, Junqi
Wang, Zhenyu
Cao, Jie
Milder symptoms and shorter course in patients with re-positive COVID-19: A cohort of 180 patients from Northeast China
title Milder symptoms and shorter course in patients with re-positive COVID-19: A cohort of 180 patients from Northeast China
title_full Milder symptoms and shorter course in patients with re-positive COVID-19: A cohort of 180 patients from Northeast China
title_fullStr Milder symptoms and shorter course in patients with re-positive COVID-19: A cohort of 180 patients from Northeast China
title_full_unstemmed Milder symptoms and shorter course in patients with re-positive COVID-19: A cohort of 180 patients from Northeast China
title_short Milder symptoms and shorter course in patients with re-positive COVID-19: A cohort of 180 patients from Northeast China
title_sort milder symptoms and shorter course in patients with re-positive covid-19: a cohort of 180 patients from northeast china
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593080/
https://www.ncbi.nlm.nih.gov/pubmed/36304945
http://dx.doi.org/10.3389/fmicb.2022.989879
work_keys_str_mv AT lihongyan mildersymptomsandshortercourseinpatientswithrepositivecovid19acohortof180patientsfromnortheastchina
AT zhumingqin mildersymptomsandshortercourseinpatientswithrepositivecovid19acohortof180patientsfromnortheastchina
AT zhangpeng mildersymptomsandshortercourseinpatientswithrepositivecovid19acohortof180patientsfromnortheastchina
AT yanxingjian mildersymptomsandshortercourseinpatientswithrepositivecovid19acohortof180patientsfromnortheastchina
AT niujunqi mildersymptomsandshortercourseinpatientswithrepositivecovid19acohortof180patientsfromnortheastchina
AT wangzhenyu mildersymptomsandshortercourseinpatientswithrepositivecovid19acohortof180patientsfromnortheastchina
AT caojie mildersymptomsandshortercourseinpatientswithrepositivecovid19acohortof180patientsfromnortheastchina